Characteristics of super-spreaders of novel coronaviruses

In a recent study posted to the medRxiv* pre-print server, researchers conducted a systematic review to evaluate the characteristics of super-spreaders of three novel coronaviruses (nCoV) that caused severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS), and coronavirus disease 2019 (COVID-19).

Study: Super-spreaders of novel coronaviruses that cause SARS, MERS and COVID-19 : A systematic review. Image Credit: Angelina Bambina/Shutterstock
Study: Super-spreaders of novel coronaviruses that cause SARS, MERS and COVID-19 : A systematic review. Image Credit: Angelina Bambina/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Most nCoV infected individuals transmit diseases to one or two individuals. However, some patients are ‘super spreaders’ – they are the primary source of several secondary infections. The identification of common factors among these super-spreaders would enable efficient containment and decrease the overall transmission of disease.

Although previous studies have reported on SARS and MERS super-spreaders, the super-spreading of COVID-19 is still taking place. Moreover, to date, the documentation of the characteristics of individual super-spreaders is limited.

About the study

In the present systematic review, researchers assessed studies reporting on the attributes of the MERS, COVID-19, and SARS super-spreaders to identify common factors among them. The index cases that transmitted infection to a minimum of nine people were considered as ‘super-spreaders’ for the present review.

Databases such as Scopus and MEDLINE were searched on June 3, 2020, and June 18, 2021, for studies on super-spreaders of MARS, COVID-19, and SARS infections. Additionally, pre-print servers such as bioRxiv and medRxiv and grey literature from credible sources or supported by public statements of the index cases themselves, interviews, or press releases were also included.

Studies were eligible for the systematic review if they were published between 2002 to mid-June 2021 in all languages, that could be translated to Spanish or English, of any study design and any study setting. These studies reported on MERS, SARS, or COVID-19 index cases diagnosed by reverse-transcription-polymerase chain reaction (rt-PCR), clinical manifestations, or cell culture with definite exposure history and transmitted infections primarily via the respiratory route face-to-face. Full-text articles selected by a minimum of two reviewers were included in the review and a third reviewer intervened in case of no consensus.

Data on sex, age, location, activities, ethnicity, occupation, transmission setting, symptom severity, medical conditions, and disease outcomes were obtained. The team recorded the count of first-generation cases and equated this to the count of secondary infections transmitted by the super-spreaders. The quality of all the studies was assessed and classified as ‘most credible’, ‘fairly credible’, or ‘poorly credible’ based on the number of ‘yes’ answers to the questions of the quality assessment checklist designed by the team.

Results

A total of 14,905 studies from Scopus and MEDLINE and 400 pre-print articles were searched using Google scholar. Of these, 14,569 were excluded during the title and abstract screening whereas 336 were retained for the full-text review. After reviewing the entire text of articles, 260 were excluded and 87 new articles were included. As a result, data was extracted from 163 studies. From these studies, 14, 76, and 29 index cases of MERS, COVID-19, and SARS were identified, respectively.

The majority of the MERS-infected super-spreaders were South Korean men and transmitted infections in clinical settings - either hospitalized due to respiratory illness or attended clinics due to other reasons such as dialysis between 2014 and 2017. Their mean age was 48 years. Most of them had symptoms of severe illness, particularly pneumonia with 67% mortality. They transmitted infections to about two to 89 people.

SARS super-spreading mainly took place in the Far East (Hong Kong, Taiwan, or China) and Canada in clinical settings between December 2002 and April 2003. Most super-spreaders were men with a mean age of 54 years with symptomatic severe disease. They caused about four to 51 secondary infections.

Most of the COVID-19 super-spreaders were identified in the United States of America (USA) after May 31, 2020 (between June and August 2020) in the initial phase of the COVID-19 wave. In contrast to the SARS and MERS outbreaks, most COVID-19 super-spreading occurred in community settings. Additionally, most of the COVID-19-infected super-spreaders were either asymptomatic or had mild disease.

While most MERS or SARS super-spreaders were symptomatic and had in-hospital deaths, most COVID-19-infected super-spreaders had mild disease and died in community areas. Data on the occupation, activities, and ethnicity of all nCoV super-spreaders were largely unavailable.  Additionally, the sex and age of COVID-19-infected super-spreaders were sparsely reported.

Overall, most super-spreaders were men aged above 40 years. Notably, most MERS and SARS super-spreaders were middle or old-aged symptomatic individuals with high in-hospital mortality whereas most COVID-19 super-spreaders were asymptomatic with mild disease irrespective of age and died in the community.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 12 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Pooja Toshniwal Paharia

Written by

Pooja Toshniwal Paharia

Pooja Toshniwal Paharia is an oral and maxillofacial physician and radiologist based in Pune, India. Her academic background is in Oral Medicine and Radiology. She has extensive experience in research and evidence-based clinical-radiological diagnosis and management of oral lesions and conditions and associated maxillofacial disorders.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Toshniwal Paharia, Pooja Toshniwal Paharia. (2023, May 12). Characteristics of super-spreaders of novel coronaviruses. News-Medical. Retrieved on October 07, 2024 from https://www.news-medical.net/news/20220318/Characteristics-of-super-spreaders-of-novel-coronaviruses.aspx.

  • MLA

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Characteristics of super-spreaders of novel coronaviruses". News-Medical. 07 October 2024. <https://www.news-medical.net/news/20220318/Characteristics-of-super-spreaders-of-novel-coronaviruses.aspx>.

  • Chicago

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Characteristics of super-spreaders of novel coronaviruses". News-Medical. https://www.news-medical.net/news/20220318/Characteristics-of-super-spreaders-of-novel-coronaviruses.aspx. (accessed October 07, 2024).

  • Harvard

    Toshniwal Paharia, Pooja Toshniwal Paharia. 2023. Characteristics of super-spreaders of novel coronaviruses. News-Medical, viewed 07 October 2024, https://www.news-medical.net/news/20220318/Characteristics-of-super-spreaders-of-novel-coronaviruses.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 increases chronic fatigue risk